Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2CNS 1Breast 1

Conditions

Colorectal Neoplasms 10Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Lung Neoplasms 2Carcinoma, Renal Cell 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Unresectable Metastatic Colorectal Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Ras-mutated Metastatic Colorectal Cancer 1Prostatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Margins of Excision 1Kidney Neoplasms 1Histiocytosis 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1

Interventions

Cisplatin 22pembrolizumab 21Carboplatin 12Radiotherapy 11Paclitaxel 11Brachytherapy 11Drug Therapy 10Bevacizumab 9Blood Specimen Collection 7Colposcopy 6Specimen Handling 5Injections 5toripalimab 4Taxes 4Surveys and Questionnaires 4Nivolumab 4Mass Screening 4Human Papillomavirus DNA Tests 4Gemcitabine 4Chemotherapy, Adjuvant 4Chemoradiotherapy 4spartalizumab 3lenvatinib 3camrelizumab 3aldesleukin 3Restraint, Physical 3Radiation 3Fulvestrant 3Cyclophosphamide 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Uterine Cervical Neoplasms × IFL protocol × Clear all
NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡